Welcome to our dedicated page for AMPIO PHARMS news (Ticker: AMPE), a resource for investors and traders seeking the latest updates and insights on AMPIO PHARMS stock.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a pre-revenue stage biotechnology company based in Greenwood Village, Colorado. The company is focused on developing innovative treatments for osteoarthritis through its OA-201 program. This program aims to develop a unique and proprietary small molecule formulation designed to alleviate pain and protect cartilage in patients suffering from osteoarthritis of the knee (OAK) and potentially other joints.
Recently, Ampio faced significant developments, including a 20-to-1 reverse stock split approved by its Board of Directors to address its stock price and meet NYSE American's listing requirements. The reverse stock split took effect in September 2023. Despite these efforts, Ampio decided to voluntarily delist its common stock from NYSE American and deregister its shares to reduce regulatory costs and conserve cash for future operations.
In the clinical field, Ampio has partnered with Ascendia Pharmaceuticals, Inc. to support the development of OA-201. Ascendia will provide comprehensive services ranging from formulation to cGMP manufacturing. Despite promising initial results, recent non-clinical studies failed to demonstrate significant pain reduction benefits, leading to the termination of the OA-201 program in February 2024.
Ampio has also been involved in legal proceedings, including securities fraud class actions and derivative actions, all of which reached settlements in early 2024. The company anticipates that the settlements will be covered by its D&O insurance policy.
The company recently announced that it will delist its common stock and terminate its reporting obligations under the Securities and Exchange Act of 1934, effective April 2024. This decision aims to preserve cash and facilitate an orderly wind down of operations.
For more information, visit the company's website or contact Ampio Pharmaceuticals directly via email at mmartino@ampiopharma.com.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the advancement of the second group in its Phase I inhaled Ampion™ clinical study for COVID-19 patients. Following a positive review from the Safety Monitoring Committee, Ampion was deemed safe and well-tolerated. The study will involve 40 patients, comparing inhaled Ampion with Standard of Care. Treatment consists of 8 mL doses inhaled four times daily for five days. Ampion's administration methods have received FDA clearance, indicating its potential for various inflammatory conditions, supported by a robust patent portfolio.
Ampio Pharmaceuticals (NYSE American: AMPE) provided a business update and third-quarter financial results on November 5, 2020. The company reported an increase in cash to $9.4 million, compared to $6.5 million at the end of 2019. Research and development costs declined by 52% to $1.7 million, while general and administrative costs also fell by 5.6%. Ampio incurred a net loss of $3.4 million, down from $7.2 million year-over-year. Key developments include ongoing clinical trials for COVID-19 therapies and adjustments to the OAK Phase III trial due to the pandemic.
Ampio Pharmaceuticals (NYSE American: AMPE) announced a business and financial update webinar on November 5, 2020, at 4:30 PM EST. Key attendees include President and CEO Michael Macaluso, Founder Dr. David Bar-Or, VP Laura Goldberg, and CFO Daniel Stokely. The webinar will feature updates on COVID-19 platforms and the OAK Trial, alongside Q3 financial insights. Participants can access the webinar through a provided link and submit questions via phone or the platform. A replay will be available shortly after the call.
Ampio Pharmaceuticals (AMPE) has initiated a Phase I trial to evaluate the safety and efficacy of inhaled Ampion for COVID-19 patients suffering respiratory distress. The trial will involve 40 patients and will compare Ampion combined with standard care versus standard care alone. Dosing begins at Penrose Hospital, Colorado Springs, with assessments focusing on safety and secondary efficacy endpoints. The FDA has granted two INDs for inhalation and intravenous use of Ampion, supporting its potential as a platform drug for various inflammatory conditions.
Ampio Pharmaceuticals, Inc. (AMPE) announced its participation at the ROTH Capital Healthcare Event, specifically the COVID-19 Therapeutics in Development webinar on October 28, 2020. This event replaces a previous announcement regarding the company’s involvement in the 2020 MedTech Innovation Forum. The webinar will focus on therapies in development for COVID-19, featuring sessions on immune modulators and antiviral agents. Ampio's future statements regarding therapeutic advancements and regulatory approvals remain forward-looking and subject to risks.
Ampio Pharmaceuticals (AMPE) announced its participation in the 2020 MedTech Innovation Forum on October 28. The presentation will focus on preliminary results from a randomized study assessing the efficacy of Ampion in hospitalized COVID-19 patients requiring supplemental oxygen. The study compared Ampion plus standard of care (SOC) against SOC alone and SOC with remdesivir. Results showed that Ampion improved average outcomes significantly, with a reduction of 3 points in the Ordinal Scale compared to lesser reductions in the other groups. The primary endpoint of safety also reported no drug-related adverse events.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the publication of a preprint report demonstrating that Ampion™ reduces pro-inflammatory cytokine release by modulating inflammatory transcription factors. The findings suggest Ampion suppresses crucial pathways, indicating its potential anti-inflammatory effects, particularly in conditions like severe COVID-19. The manuscript supports safety and tolerability observed in prior trials. Ampion has a robust patent portfolio and could receive 12-year FDA market exclusivity upon approval as a novel biologic.
Ampio Pharmaceuticals announced the FDA's approval of an Investigational New Drug (IND) for its inhalable treatment, Ampion, targeting respiratory distress caused by COVID-19. This follows a positive Phase I trial for intravenous Ampion. The new clinical trial will assess safety and efficacy among 40 hospitalized patients, with the inhalation method allowing for targeted lung treatment. Previous studies indicated that Ampion is safe for inhalation and effective in reducing tissue damage-related signaling proteins. Ampio aims to leverage Ampion's potential across multiple inflammatory conditions.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the completion of a Phase I trial for intravenous Ampion™ targeting COVID-19 patients, led by Dr. Michael Roshon from Penrose-St. Francis Hospital. The trial results were featured in a FOX news segment titled "Colorado Drug shows promise against COVID-19". Ampion is being developed to address prevalent inflammatory conditions with limited treatment options, boasting a strong patent portfolio and potential FDA exclusivity upon approval. For more details, view the full news segment at kdvr.com.
Ampio Pharmaceuticals, Inc. (AMPE) announced positive early trial results for intravenous Ampion treatment targeting COVID-19 patients. The Phase I trial involved hospitalized adults receiving supplemental oxygen and showed that IV Ampion met its primary safety endpoint, with no significant adverse events. Patients receiving Ampion exhibited stronger clinical improvements at discharge compared to the control group, which included standard care treatments. The company is set to proceed with further assessments and plans for a Phase II/III trial.
FAQ
What is the current stock price of AMPIO PHARMS (AMPE)?
What is the market cap of AMPIO PHARMS (AMPE)?
What is Ampio Pharmaceuticals' focus area?
What is the recent change in Ampio's stock structure?
Who is Ampio's partner in developing OA-201?
What happened to Ampio's OA-201 program?
What legal issues has Ampio faced recently?
Why is Ampio delisting its stock from the NYSE American?
When will Ampio's delisting become effective?
Will Ampio continue to report to the SEC?
Is Ampio still developing treatments for osteoarthritis?
How can I get more information about Ampio Pharmaceuticals?
